Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial
Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial
Phase 3 KEYFORM-008 trial evaluated the fixed-dose combination of favezelimab and pembrolizumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL) whose disease has progressed following prior anti-PD-1 therapy.
第3阶段KEYFORm-008试验评估了一种固定剂量的favezelimab和pembrolizumab联合治疗方案，适用于在先前抗PD-1疗法后疾病进展的复发性或难治性经典霍奇金淋巴瘤（cHL）患者。
Patients currently in this trial may continue on therapy until study completion. KEYFORM-008 is the only Phase 3 study in the KEYFORM clinical development program for which results are not available.
目前参加本试验的患者可以继续治疗，直到研究完成。KEYFORm-008是KEYFORm临床开发计划中唯一一项结果尚未公布的第3阶段研究。
The company has made this decision after a thorough evaluation of data from the favezelimab clinical program and will prioritize the development of other candidates in its comprehensive and diversified oncology pipeline. This decision is not based on any concerns about the safety of this fixed-dose combination.
该公司经过对favezelimab临床项目数据的全面评估后作出了这一决定，并将优先发展其综合多样化的肿瘤学管道中的其他候选药物。这个决定并不是基于对这种固定剂量联合治疗方案安全性的任何担忧。
